Clinical trials: Tregs
RCC, Metastatic Renal Cell Carcinoma
Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve Efficacy
The project aims to identify Nivolumab predictive biomarkers in metastatic renal cancer patients through functional evaluation of peripheral Tregs and NKs.
- Trial name
- REVOLUTION (NCT03891485)
- Testing
- Immunological and tumour characterization
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- National Cancer Institute, Naples
Henoch Schönlein Purpura
Study of the Role of Regulator T Cells in the Pathophysiology of Childhood Henoch Schönlein Purpura
The primary objective of this study is to search for evidence of quantitative or functional defects in plasma regulatory T cells (Tregs) in pediatric patients with Henoch Schönlein Purpura (HSP) as compared to a control…
- Trial name
- FOX-TREG (NCT02317133)
- Testing
- Blood samples, Stool samples
- Where
- 2 sites in France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Immune Tolerance, Food Tolerance
Tregs and miRNAs in Breast Milk: Effects on Infant Food Tolerance
This prospective observational study aims to identify and characterize immunoregulatory microRNAs (miRNAs) associated with regulatory T cells (Tregs) in human breast milk and to evaluate their temporal expression patterns.
- Trial name
- NCT07744373
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Istanbul University
Metastatic Colorectal Cancer
Circulating Regulatory Lymphocytes and Outcome of Metastatic Colorectal Cancer Patients
Aim of the present study is to investigate whether baseline or early post-treatment (one month after treatment commencement) frequency of peripheral T regulatory lymphocytes (Tregs OR CD4+/CD25high/FOXP3+ T cells), known to…
- Trial name
- NCT01533740
- Testing
- fluorouracil/irinotecan/levo-folinic acid/bevacizumab
- Where
- Italy
- Volunteers
- 31 people
- Sponsor
- University of Rome Tor Vergata
Conjunctivitis, Allergic
Treg Effector Function and Th2/Treg Ratio in Allergic Conjunctivitis: Effect of Desensitization Therapy
This study aims to evaluate the effector function and expression of TIGIT and PD-1 on Tregs, as well as the Th2/Treg ratio, in patients with allergic conjunctivitis with and without desensitization therapy, compared to healthy…
- Trial name
- INMUNOREG (NCT07171307)
- Where
- Mexico
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Instituto de Oftalmología Fundación Conde de Valenciana
The Immune Dysregulation Polyendocrinopathy Enteropathy X-linked Syndrome is a Primary Immunodeficiency Caused by Pathogenic Variants in Forkhead Box Protein 3
Study Evaluating a Gene Therapy for IPEX Syndrome Through the Expression of FOXP3 on Deficient T Cells to Produce Tregs-like.
The purpose of this study is to evaluate the safety and efficacy of FOXP3-T4 (an autologous gene therapy) alone or in combination with low-dose IL-2 for the treatment of IPEX syndrome.
- Trial name
- THERIPEX (NCT07697118)
- Testing
- FOXP3-T4 drug product, ILT-101
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Steroid Refractory Graft Versus Host Disease
CK0802 for Treatment of Steroid Refractory Graft vs. Host Disease (GVHD)
The purpose of this study is to determine the efficacy and safety of CK0802 Tregs for treatment of refractory GVHD (graft-versus-host disease)
- Trial name
- NCT07576699
- Testing
- CK0802 (Allogeneic, Cryopreserved, Cord blood-derived T-regulatory cells, cells that are not HLA matched)
- Volunteers
- 12 people
- Sponsor
- Cellenkos, Inc.
Tuberculosis
Study to Evaluate the Tolerability and Immunogenicity of Nyaditum Resae ® Probiotic Administered to Pediatric Population in Contact With Tuberculosis With or Without Latent Tuberculosis Infection
This is a doble-blind, masked, compared with placebo clinical trial in pediatric population in contact with tuberculosis with or without tuberculosis infection.
- Trial name
- NCT02581579
- Testing
- Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis
- Where
- 3 sites in Spain
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Manresana de Micobacteriologia, SL
Presymptomatic Diabetes Type 1 (Stage 1), Diabetes Mellitus, Type I
Treatment of Presymptomatic (Stage 1) Type 1 Diabetes Pediatric Patients With Treg Cell Preparations and Anti-CD20 Antibody
The main purpose of the study is to check: Can therapy with a preparation of regulatory cells (Tregs lymphocytes) and/or an anti-CD20 antibody preparation (rituximab) be successfully used in children with pre-diabetes to treat or…
- Conditions
- Presymptomatic Diabetes Type 1 (Stage 1), Diabetes Mellitus, Type I, Diabetes Mellitus, Type 1
- Trial name
- PreTreg (NCT06688331)
- Testing
- ex vivo expanded CD4+CD25+CD127- regulatory T cells (Tregs), Anti-CD20 (rituximab)
- Where
- 9 sites in Poland
- Volunteers
- 150 people
- Sponsor
- PolTREG S.A.
Vitiligo, CD25 Deficiency
Tregs CD25 CXCL9 in Vitiligo
Clinical significance of circulating T regulatory cells , soluble CD25 and CXCL9 to assess disease activity of vitiligo.
- Conditions
- Vitiligo, CD25 Deficiency, Chemokine (C-X-C Motif), Tregs
- Trial name
- NCT05569096
- Testing
- ELIZA , Flowcytometry
- Volunteers
- 40 people
- Sponsor
- Assiut University
Type 1 Diabetes Mellitus
Immunotherapy with Autologous Tregs in T1DM
Type 1 diabetes (T1D) is an autoimmune disease characterized by a progressive immune distruction of pancreat beta cells and deterioration of endogenous insulin secretion.
- Trial name
- NCT06708780
- Testing
- Ex vivo Expanded Human Autologous Regulatory T Cells, Routine Care
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Sepsis, Septic Shock
Immune Failure in Critical Therapy (INFECT) Study
Patients admitted to intensive care units (ICU) are at high risk of developing secondary infections, and this is in part due to dysfunction or failure of their 'germ killing' functions (the immune system).
- Trial name
- INFECT (NCT02186522)
- Where
- 4 sites in United Kingdom
- Volunteers
- 168 people
- Sponsor
- University of Edinburgh